Oral and perioral herpes simplex virus type 1 (HSV-1) infection: review of its management
- PMID: 16700734
- DOI: 10.1111/j.1601-0825.2006.01202.x
Oral and perioral herpes simplex virus type 1 (HSV-1) infection: review of its management
Abstract
Herpes simplex virus type 1 (HSV-1) gives rise to a variety of clinical disorders and is a major cause of morbidity and mortality worldwide. HSV-1 infections are common in oral and perioral area. The aim of the present report was to critically examine the published literature to evaluate the advantages and limitations of therapy of HSV-1 infection in both immunocompetent and immunocompromised patients. Systemic antiviral therapy has been widely accepted as effective for primary herpetic gingivostomatitis. Aciclovir (ACV) 5% cream seems to be the accepted standard topical therapy for herpes labialis, being both effective and well tolerated, although penciclovir 1% cream has been proposed as a potentially useful treatment. Systemic ACV may be effective in reducing the duration of symptoms of recurrent HSV-1 infection, but the optimal timing and dose of the treatment are uncertain. Aciclovir and famciclovir may be of benefit in the acute treatment of severe HSV-1 disease in immunocompromised patients. There is also evidence that prophylactic oral ACV may reduce the frequency and severity of recurrent attack of herpetic infection in immunocompromised patients, but the optimal timing and duration of treatment is uncertain and can vary in different situations.
Similar articles
-
Herpes simplex type-1 virus infection.Quintessence Int. 2003 Jun;34(6):453-67. Quintessence Int. 2003. PMID: 12859090 Review.
-
Herpes Simplex Virus Type 1 infection: overview on relevant clinico-pathological features.J Oral Pathol Med. 2008 Feb;37(2):107-21. doi: 10.1111/j.1600-0714.2007.00586.x. J Oral Pathol Med. 2008. PMID: 18197856 Review.
-
Profiling penciclovir susceptibility and prevalence of resistance of herpes simplex virus isolates across eleven clinical trials.Arch Virol. 2003 Sep;148(9):1757-69. doi: 10.1007/s00705-003-0124-7. Arch Virol. 2003. PMID: 14505088 Clinical Trial.
-
An update on short-course intermittent and prevention therapies for herpes labialis.Herpes. 2007 Jun;14 Suppl 1:13A-18A. Herpes. 2007. PMID: 17877887 Review.
-
Oral herpes simplex virus infection in pregnancy: what are the concerns?J Can Dent Assoc. 2009 Sep;75(7):523-6. J Can Dent Assoc. 2009. PMID: 19744363 Review.
Cited by
-
Oral and dental health in head and neck cancer survivors.Cancers Head Neck. 2016 Oct 19;1:14. doi: 10.1186/s41199-016-0015-8. eCollection 2016. Cancers Head Neck. 2016. PMID: 31093344 Free PMC article. Review.
-
Total dysphagia after short course of systemic corticotherapy: herpes simplex virus esophagitis.World J Gastroenterol. 2013 Aug 21;19(31):5178-81. doi: 10.3748/wjg.v19.i31.5178. World J Gastroenterol. 2013. PMID: 23964155 Free PMC article.
-
Herpes labialis and Nigerian dental health care providers: knowledge, attitudes, behaviors, and refusal to treat.BMC Health Serv Res. 2015 Sep 15;15:383. doi: 10.1186/s12913-015-1023-9. BMC Health Serv Res. 2015. PMID: 26373396 Free PMC article.
-
Protocol for a randomised controlled trial of 90% kanuka honey versus 5% aciclovir for the treatment of herpes simplex labialis in the community setting.BMJ Open. 2017 Aug 3;7(8):e017766. doi: 10.1136/bmjopen-2017-017766. BMJ Open. 2017. PMID: 28775197 Free PMC article. Clinical Trial.
-
CXCL9 compensates for the absence of CXCL10 during recurrent Herpetic stromal keratitis.Virology. 2017 Jun;506:7-13. doi: 10.1016/j.virol.2017.02.022. Epub 2017 Mar 7. Virology. 2017. PMID: 28282568 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical